Induction and add-on therapy with Mitoxantrone and Interferon beta in multiple sclerosis

Mauro Zaffaroni, Annalisa Rizzo, Silvana Maria Baldini, Angelo Ghezzi, Giancarlo Comi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We retrospectively analyzed data from 70 multiple sclerosis (MS) patients treated with mitoxantrone (MX) before Interferon-β (IFN-β) because of clinically and MRI very active isolated syndrome (CIS) or relapsing-remitting MS (induction therapy) or due to breakthrough/persistently active disease in spite of IFN-β (add-on/ combination therapy), or for increased disability suggesting a secondary progression (rescue therapy). After almost 2-year follow-up, relapse rate and disability decreased very significantly in the two former groups while MX was essentially ineffective as rescue therapy. Induction therapy is a valid option for very aggressive/active CIS and MS at onset.

Original languageEnglish
JournalNeurological Sciences
Volume29
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Mitoxantrone
Interferon-beta
Multiple Sclerosis
Interferons
Therapeutics
Relapsing-Remitting Multiple Sclerosis
Recurrence

Keywords

  • Combination therapy
  • Glatiramer acetate
  • Induction therapy
  • Interferon beta
  • Mitoxantrone
  • Rescue therapy

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Induction and add-on therapy with Mitoxantrone and Interferon beta in multiple sclerosis. / Zaffaroni, Mauro; Rizzo, Annalisa; Baldini, Silvana Maria; Ghezzi, Angelo; Comi, Giancarlo.

In: Neurological Sciences, Vol. 29, No. SUPPL. 2, 09.2008.

Research output: Contribution to journalArticle

Zaffaroni, Mauro ; Rizzo, Annalisa ; Baldini, Silvana Maria ; Ghezzi, Angelo ; Comi, Giancarlo. / Induction and add-on therapy with Mitoxantrone and Interferon beta in multiple sclerosis. In: Neurological Sciences. 2008 ; Vol. 29, No. SUPPL. 2.
@article{82e3cc7649f847e283a254b16e48a6ec,
title = "Induction and add-on therapy with Mitoxantrone and Interferon beta in multiple sclerosis",
abstract = "We retrospectively analyzed data from 70 multiple sclerosis (MS) patients treated with mitoxantrone (MX) before Interferon-β (IFN-β) because of clinically and MRI very active isolated syndrome (CIS) or relapsing-remitting MS (induction therapy) or due to breakthrough/persistently active disease in spite of IFN-β (add-on/ combination therapy), or for increased disability suggesting a secondary progression (rescue therapy). After almost 2-year follow-up, relapse rate and disability decreased very significantly in the two former groups while MX was essentially ineffective as rescue therapy. Induction therapy is a valid option for very aggressive/active CIS and MS at onset.",
keywords = "Combination therapy, Glatiramer acetate, Induction therapy, Interferon beta, Mitoxantrone, Rescue therapy",
author = "Mauro Zaffaroni and Annalisa Rizzo and Baldini, {Silvana Maria} and Angelo Ghezzi and Giancarlo Comi",
year = "2008",
month = "9",
doi = "10.1007/s10072-008-0946-x",
language = "English",
volume = "29",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Induction and add-on therapy with Mitoxantrone and Interferon beta in multiple sclerosis

AU - Zaffaroni, Mauro

AU - Rizzo, Annalisa

AU - Baldini, Silvana Maria

AU - Ghezzi, Angelo

AU - Comi, Giancarlo

PY - 2008/9

Y1 - 2008/9

N2 - We retrospectively analyzed data from 70 multiple sclerosis (MS) patients treated with mitoxantrone (MX) before Interferon-β (IFN-β) because of clinically and MRI very active isolated syndrome (CIS) or relapsing-remitting MS (induction therapy) or due to breakthrough/persistently active disease in spite of IFN-β (add-on/ combination therapy), or for increased disability suggesting a secondary progression (rescue therapy). After almost 2-year follow-up, relapse rate and disability decreased very significantly in the two former groups while MX was essentially ineffective as rescue therapy. Induction therapy is a valid option for very aggressive/active CIS and MS at onset.

AB - We retrospectively analyzed data from 70 multiple sclerosis (MS) patients treated with mitoxantrone (MX) before Interferon-β (IFN-β) because of clinically and MRI very active isolated syndrome (CIS) or relapsing-remitting MS (induction therapy) or due to breakthrough/persistently active disease in spite of IFN-β (add-on/ combination therapy), or for increased disability suggesting a secondary progression (rescue therapy). After almost 2-year follow-up, relapse rate and disability decreased very significantly in the two former groups while MX was essentially ineffective as rescue therapy. Induction therapy is a valid option for very aggressive/active CIS and MS at onset.

KW - Combination therapy

KW - Glatiramer acetate

KW - Induction therapy

KW - Interferon beta

KW - Mitoxantrone

KW - Rescue therapy

UR - http://www.scopus.com/inward/record.url?scp=53649090647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53649090647&partnerID=8YFLogxK

U2 - 10.1007/s10072-008-0946-x

DO - 10.1007/s10072-008-0946-x

M3 - Article

C2 - 18690501

AN - SCOPUS:53649090647

VL - 29

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 2

ER -